Over the past two years, COVID-19 has been the dominant topic in healthcare conversations. In 2023, we are still witnessing an increasing influx of investment capital into the healthcare sector. Obesity drugs, such as Wegovy and Ozempic by Novo Nordisk, have demonstrated blockbuster potential and gained popularity in the market.
As the world slowly returns to a pre-COVID state, the emergence of technologies like artificial intelligence (AI) and Machine Learning (ML) has enabled biotech companies to significantly enhance and develop treatments, products, and services. The interests in the healthcare sector have been growing rapidly as it offers investors a wide range of investment opportunities, with companies constantly innovating to improve the quality of life and productivity in medical aspects.
GCFF 2023 Virtual Conference – Healthcare Conference (Asia Pacific), a free webinar, will be held on Nov 29, 2023 and will provide institutional/industrial investors with:
North American Life Science Market Insights and Outlook reported by NAI500.
Promising projects presented by biotech companies in North America and Greater China.
Various topics including innovative therapies, pharmaceutical R&D, epigenetics, cancer treatment.
Simultaneous English & Mandarin interpretation.
Organizer
Co-Organizer
Supporting Organizations
Who will be Watching?
In this Asia investor focused event, participating companies will have the benefit of presenting to the qualified investors in Asia who have strong interests in the healthcare sector. These investors will include high-net-worth individuals, institutional investors, private family offices or industrial corporate investor groups. This is an invitation-only event with the focus on regions including mainland China, Hong Kong, Taiwan and Singapore.
This will be the perfect opportunity for companies in the healthcare sector to expand their presence with the growing number of investors in the Asia Pacific region. If you are interested in attending this event as an investor, please contact us for more info.
